Vertex Pharmaceuticals Gets 96% of Product Sales From Treatments for 1 Disease. Here's Why That's About to Change.

VRTX still pulls 96% of its product sales from cystic fibrosis treatments, but the company is building a case that concentration is about to loosen. Management expects $500 million-plus in 2026 sales from new products.

Q2 revenue hit $3.33 billion, up 12% year over year, and Vertex raised full-year guidance. That backdrop gives the diversification push a funded runway rather than a rescue narrative.

The pipeline spans several areas:

• ▸Journavx: a pain relief drug.
• ▸Casgevy: a gene-editing therapy developed with CRSP.
• ▸Inaxaplin: a kidney disease therapy.
• ▸Crinetics Pharmaceuticals: a $10 billion acquisition that adds endocrine disease treatments.

Interpretation: the $500 million-plus 2026 target is small against a $3.33 billion quarterly run rate, so new products would still be a minor share of revenue next year. The investment case rests on whether these launches scale beyond that figure, not on near-term mix shift. The $10 billion Crinetics deal signals management is willing to spend heavily to reduce single-franchise dependence.

CRSP carries separate exposure through Casgevy, since it shares that program with VRTX. Casgevy's uptake is one of the few new-product data points where both tickers can move on the same news.